Efinaconazole

An antifungal medication used to treat onychomycosis

Efinaconazole
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Efinaconazole is a topical antifungal medication primarily used for the treatment of onychomycosis, a fungal infection of the nails. It is marketed under the brand name Jublia, among others. Efinaconazole is notable for its ability to penetrate the nail plate and reach the site of infection effectively.

Mechanism of Action

Efinaconazole is an azole antifungal, which works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes. By disrupting the production of ergosterol, efinaconazole compromises the integrity of the fungal cell membrane, leading to cell death.

Clinical Use

Efinaconazole is specifically indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes. It is applied topically once daily to the affected toenail(s) for a duration of 48 weeks.

Pharmacokinetics

Efinaconazole is formulated as a 10% solution for topical application. The medication is designed to penetrate the nail plate and reach the nail bed, where the fungal infection resides. Systemic absorption is minimal, which reduces the risk of systemic side effects.

Side Effects

Common side effects of efinaconazole include application site reactions such as dermatitis, pruritus, and erythema. These side effects are generally mild and resolve without the need for discontinuation of therapy.

Advantages

Efinaconazole offers several advantages over other topical antifungal treatments, including its ability to penetrate the nail plate without the need for debridement or removal of the nail. This makes it a convenient option for patients who prefer non-invasive treatment methods.

Related pages

• Onychomycosis
• Antifungal
• Azole

• 
  Efinaconazole